SCHEMBL2071199

SCHEMBL2071199

Cc1cc(C)c(-c2cn(C)c3nc(NCCOc4ccccc4)n(C)c(=O)c23)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 7/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 1/20 0.50
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 2/20 0.40
ATM Q13315 1/20 0.40
HIF1A Q16665 1/20 0.39
MPO P05164 1/20 0.39
GPR18 Q14330 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA2B P29275 1/20 0.37
ADORA1 P30542 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072342 0.86 CRHR1 (0.57) CRHR1SMN1; SMN2GAAPOLBLMNA
SCHEMBL2071182 0.82 CRHR1 (0.70) CRHR1LMNAKMT2AADORA2AADORA1
SCHEMBL2072641 0.80 CRHR1 (0.66) CRHR1SMN1; SMN2LMNAHTTRAB9A
SCHEMBL2071464 0.80 CRHR1 (0.53) CRHR1SMN1; SMN2GAALMNAHTT
SCHEMBL2071039 0.75 CRHR1 (0.54) CRHR1SMN1; SMN2GAAPOLBLMNA
SCHEMBL2072033 0.75 CRHR1 (0.52) CRHR1SMN1; SMN2GAAPOLBHIF1A
SCHEMBL2073108 0.74 CRHR1 (0.63) CRHR1ALDH1A1
SCHEMBL2072415 0.74 CRHR1 (0.55) CRHR1SMN1; SMN2LMNAHTT
SCHEMBL2070099 0.73 CRHR1 (0.62) CRHR1ALDH1A1
SCHEMBL2070434 0.73 CRHR1 (0.49) CRHR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R CRHR1 1/4885SMN1; SMN2 4009/4885GAA 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.